The observational clinical study will recruit 50 recurrent and/or metastaticnasopharyngeal carcinoma (r/mNPC) patients, to investigate the prediction values ofmulti-omics technique for the efficacy of chemoradiotherapy combined with immunotherapy.
Not Provided
Drug: cisplatin-based chemoradiotherapy combined with immunotherapy
Chemotherapy:cisplatin-based chemotherapy
GP/TP/PF/TPF
Choice of chemotherapy regimen is decided by patient's doctor in charge.
Radiation: Intensity Modulated Radiation Therapy
All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with
MR fusion images in the treatment planning system. The target volumes are defined in
accordance with the International Commission on Radiation Units and Measurements Reports
83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary
tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1
(High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target
volume) in 30-32 fractions. The details of dose limits for organs at risk are based on
the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
Immunotherapy:PD-1 blocking antibody
Inclusion Criteria:
- Recurrent or metastatic nasopharyngeal carcinoma patients
- All genders，range from 18～70 years old
- ECOG score 0 ~ 1
- Inform consent form
Exclusion Criteria:
- Have or are suffering from other malignant tumors;
- Participating in other clinical trials;
- Drug or alcohol addition;
- Do not have full capacity for civil acts;
- Mental disorder;
- Pregnancy or lactation;
- Severe complication, eg, uncontrolled hypertension.
Cancer Center, Sun Yat-sen University
Guangzhou, Guangdong, China
Investigator: Chong Zhao, M.D
Contact: 02087342638
zhaochong@sysucc.org.cn
Jingjing Miao, M.D
86-13631355201
miaojingjing90@163.com
Chong Zhao, M.D, Principal Investigator
Sun Yat-sen University